|153.80||+0.6400||+0.42%||Vol 4.40M||1Y Perf 34.05%|
|Jul 1st, 2022 16:04 DELAYED|
|- -||-2.05 -1.33%|
|Target Price||165.00||Analyst Rating||Moderate Buy 1.97|
|Potential %||7.28||Finscreener Ranking||+ 38.37|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★+ 42.98|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★+ 48.54|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★ 37.63|
|Price Range Ratio 52W %||68.57||Earnings Rating||Sell|
|Market Cap||271.78B||Earnings Date||29th Jul 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||29th Jul 2022|
|Estimated EPS Next Report||3.43|
|EPS Growth Next 5 Years %||2.50|
|Avg. Weekly Volume||6.26M|
|Avg. Monthly Volume||6.23M|
|Avg. Quarterly Volume||7.08M|
AbbVie Inc. (NYSE: ABBV) stock closed at 153.8 per share at the end of the most recent trading day (a 0.42% change compared to the prior day closing price) with a volume of 4.40M shares and market capitalization of 271.78B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 50000 people. AbbVie Inc. CEO is Richard A. Gonzalez.
The one-year performance of AbbVie Inc. stock is 34.05%, while year-to-date (YTD) performance is 13.59%. ABBV stock has a five-year performance of 112.11%. Its 52-week range is between 105.56 and 175.91, which gives ABBV stock a 52-week price range ratio of 68.57%
AbbVie Inc. currently has a PE ratio of 21.90, a price-to-book (PB) ratio of 16.53, a price-to-sale (PS) ratio of 4.77, a price to cashflow ratio of 11.90, a PEG ratio of 2.32, a ROA of 8.70%, a ROC of 15.29% and a ROE of 84.89%. The company’s profit margin is 22.20%, its EBITDA margin is 43.60%, and its revenue ttm is $56.73 Billion , which makes it $32.10 revenue per share.
Of the last four earnings reports from AbbVie Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $3.43 for the next earnings report. AbbVie Inc.’s next earnings report date is 29th Jul 2022.
The consensus rating of Wall Street analysts for AbbVie Inc. is Moderate Buy (1.97), with a target price of $165, which is +7.28% compared to the current price. The earnings rating for AbbVie Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AbbVie Inc. has a dividend yield of 3.68% with a dividend per share of $5.64 and a payout ratio of 134.00%.
AbbVie Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 5.56, ATR14 : 3.68, CCI20 : 89.85, Chaikin Money Flow : 0.09, MACD : 1.10, Money Flow Index : 67.89, ROC : 11.76, RSI : 60.86, STOCH (14,3) : 86.48, STOCH RSI : 0.80, UO : 55.90, Williams %R : -13.52), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AbbVie Inc. in the last 12-months were: Brian L. Durkin (Option Excercise at a value of $1 363 676), Brian L. Durkin (Sold 30 418 shares of value $4 309 432 ), Carrie C. Strom (Sold 7 453 shares of value $945 083 ), Elaine K. Sorg (Option Excercise at a value of $809 669), Elaine K. Sorg (Sold 22 793 shares of value $2 937 436 ), Henry O. Gosebruch (Option Excercise at a value of $4 606 045), Henry O. Gosebruch (Sold 123 960 shares of value $18 919 823 ), Jeffrey Ryan Stewart (Option Excercise at a value of $1 630 387), Jeffrey Ryan Stewart (Sold 51 330 shares of value $7 869 429 ), Laura J. Schumacher (Option Excercise at a value of $10 381 360), Laura J. Schumacher (Sold 181 670 shares of value $23 660 677 ), Michael Severino (Option Excercise at a value of $41 222 566), Michael Severino (Sold 579 801 shares of value $88 227 551 ), Richard A. Gonzalez (Option Excercise at a value of $10 682 776), Richard A. Gonzalez (Sold 174 100 shares of value $21 453 641 ), Robert A. Michael (Sold 43 105 shares of value $6 390 245 ), Roxanne S. Austin (Sold 71 844 shares of value $8 377 984 ), Timothy J. Richmond (Option Excercise at a value of $2 964 608), Timothy J. Richmond (Sold 76 782 shares of value $9 960 768 )
Tue, 24 May 2022 02:06 GMT AbbVie (ABBV) Receives a New Rating from SVB Securities- TipRanks. All rights reserved.
Thu, 12 May 2022 12:49 GMT AbbVie (ABBV) Received its Third Buy in a Row- TipRanks. All rights reserved.
Sat, 23 Apr 2022 03:28 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: AbbVie (ABBV) and Quest Diagnostics (DGX)- TipRanks. All rights reserved.
Tue, 19 Apr 2022 16:08 GMT AbbVie: Why Its an Excellent Recession-Resistant Stock- TipRanks. All rights reserved.
Fri, 15 Apr 2022 03:26 GMT AbbVie (ABBV) Gets a Buy Rating from Wells Fargo- TipRanks. All rights reserved.
Tue, 12 Apr 2022 13:23 GMT AbbVie: Great Company, Future Upside Likely Weakened- TipRanks. All rights reserved.
Fri, 11 Mar 2022 15:16 GMT AbbVie Stock: Strong Partnerships Bode Well- TipRanks. All rights reserved.
Fri, 11 Mar 2022 14:18 GMT BMO Capital Believes AbbVie (ABBV) Still Has Room to Grow- TipRanks. All rights reserved.
Thu, 10 Mar 2022 17:35 GMT Mizuho Securities Believes AbbVie (ABBV) Wont Stop Here- TipRanks. All rights reserved.
Mon, 07 Feb 2022 14:17 GMT AbbVie Stock Has Further to Climb- TipRanks. All rights reserved.
Thu, 27 Jan 2022 12:37 GMT AbbVie (ABBV) Gets a Buy Rating from Mizuho Securities- TipRanks. All rights reserved.
Wed, 05 Jan 2022 08:11 GMT What Do Neurocrines Newly Added Risk Factors Tell Investors- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.